[LANCET] Quantitative flow ratio versus fractional flow reserve for coronary revascularisation guidance (FAVOR III Europe): a multicentre, randomised, non-inferiority trial

Post time 6 day(s) ago

journal：LANCET

Authors：Birgitte Krogsgaard Andersen, MDa ∙ Martin Sejr-Hansen, MDa ∙ Luc Maillard, MD PhDb ∙ Prof Gianluca Campo, MD PhDc ∙ Truls Råmunddal, MD PhDd ∙ Prof Barbara E Stähli, MD MPHe ∙ Vincenzo Guiducci, MDf ∙ Luigi Di Serafino, MD PhDg ∙ Prof Javier Escaned, MD PhDh,i ∙ Ignacio Amat Santos, MD PhDj ∙ Ramón López-Palop, MD PhDk ∙ Prof Ulf Landmesser, MDl,m ∙ Ruthe Storgaard Dieu, PhDa ∙ Hernán Mejía-Rentería, MD PhDh ∙ Lukasz Koltowski, MD PhDn ∙ Greta Žiubrytė, MDo,p ∙ Laura Cetran, MD PhDq ∙ Julien Adjedj, MD PhDr ∙ Youssef S Abdelwahed, MD PhDl,m ∙ Tommy Liu, MDs ∙ Lone Juul Hune Mogensen, MStata ∙ Ashkan Eftekhari, MD PhDt ∙ Jelmer Westra, MD PhDa ∙ Karsten Lenk, MDu ∙ Gianni Casella, MD PhDv ∙ Prof Eric Van Belle, MD PhDw ∙ Simone Biscaglia, MD PhDc ∙ Niels Thue Olsen, MD PhDx ∙ Prof Paul Knaapen, MD PhDy ∙ Janusz Kochman, MDn ∙ Ramón Calviño Santos, MDz ∙ Roberto Scarsini, MD PhDaa ∙ Prof Evald Høj Christiansen, MD PhDa ∙ Niels Ramsing Holm, MD

Published date：November 09, 2024

DOI：10.1016/S0140-6736(24)02175-5

Article link：https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(24)02175-5/abstract

Post time 6 day(s) ago

: This post has been completed
Completed attachments will be deleted within 24 hours.

[Other] [LANCET] Quantitative flow ratio versus fractional flow reserve for coronary revascularisation guidance (FAVOR III Europe): a multicentre, randomised, non-inferiority trial

Best Answer

Same Category

Latest Reply

Announcement

Daily Top Contributors

[Other] [LANCET] Quantitative flow ratio versus fractional flow reserve for coronary revascularisation guidance (FAVOR III Europe): a multicentre, randomised, non-inferiority trial Copy

Best Answer

Same Category

Latest Reply

Announcement

Daily Top Contributors

[Other] [LANCET] Quantitative flow ratio versus fractional flow reserve for coronary revascularisation guidance (FAVOR III Europe): a multicentre, randomised, non-inferiority trial